US20100042168A1 - Electronic system for influencing cellular functions in a warm-blooded mammalian subject - Google Patents

Abstract

An electronic system activatable by electrical power is described. The system is useful for influencing cellular functions or malfunctions in a warm-blooded mammalian subject. The system includes one or more controllable low energy HF (High Frequency) carrier signal generator circuits, one or more data processors for receiving control information, one or more amplitude modulation control generators and one or more amplitude modulation frequency control generators. The amplitude modulation frequency control generators are adapted to accurately control the frequency of the amplitude modulations to within an accuracy of at least 1000 ppm, most preferably to within about 1 ppm, relative to one or more determined or predetermined reference amplitude modulation frequencies.

Description

FIELD OF THE INVENTION
• This invention relates to an electronic system for influencing cellular functions in a warm-blooded mammalian subject. More particularly, the invention concerns research findings related to how earlier electronic systems may be modified and programmed to achieve both improved and additional therapeutic effects.
BACKGROUND OF THE INVENTION
• Reference is made to European Patent EP 0 592 851 B1 and corresponding Patents and Patent Applications and to the various publications referred to therein. Since the time of the priority Application filed in the USA on 25 Sep. 1992 (U.S. Ser. No 951,563 now U.S. Pat. No. 5,441,528), a number of further publications related to effects of very low energy electromagnetic fields on patients suffering from insomnia and/or anxiety disorders have taken place:
• Koziol J A, Erman M, Pasche B, Hajdukovic R, Mitler MM (1993) Assessing a changepoint in a sequence of repeated measurements with application to a low-energy emission therapy sleep study. J Applied Statistics 20: 393-400
• Amato D, Pasche B (1993) An evaluation of the safety of low energy emission therapy. Compr Ther 19: 242-247
• Higgs L, Reite M, Barbault A, Lebet J P, Rossel C, Amato D, Dafni U, Pasche B (1994) Subjective and Objective Relaxation Effects of Low Energy Emission Therapy. Stress Medicine 10: 5-13
• Reite M, Higgs L, Lebet J P, Barbault A, Rossel C, Kuster N, Dafni U, Amato D, Pasche B (1994) Sleep Inducing Effect of Low Energy Emission Therapy. Bioelectromagnetics 15: 67-75
• Lebet J P, Barbault A, Rossel C, Tomic Z, Reite M, Higgs L, Dafni U, Amato D, Pasche B (1996) Electroencephalographic changes following low energy emission therapy. Ann Biomed Eng 24: 424-429
• Pasche B, Erman M, Hayduk R, Mitler M, Reite M, Higgs L, Dafni U, Amato D, Rossel C, Kuster N, Barbault A, Lebet J-P (1996) Effects of Low Energy Emission Therapy in chronic psychophysiological insomnia. Sleep 19: 327-336
• Kelly T L, Kripke D F, Hayduk R, Ryman D, Pasche B, Barbault A (1997) Bright light and LEET effects on circadian rhythms, sleep and cognitive performance. Stress Medicine 13: 251-258
• Pasche B, Barbault A (2003) Low-Energy Emission Therapy: Current Status and Future Directions. In Bioelectromagnetic Medicine, Rosch P J, Markov M S (eds) pp 321-327. Marcel Dekker, Inc.: New York, N.Y.
• The above publications are related to an earlier device, system and use thereof described in said EP 0 592 851 B1. The improved electronic system and programmed control thereof in accordance with the present invention, however, has been determined to find therapeutic application not only for influencing cellular functions (or malfunctions) leading to central nervous system (CNS) disorders, but more particularly for influencing other cellular functions (or malfunctions) including directly or indirectly influencing cancerous cell growth or proliferation thereof in warm-blooded mammalian subjects. The direct or indirect influence on cancerous cell growth may involve but is not necessarily limited to any of prophylactic avoidance of cancerous cell formation, influencing of cell functions such as for example influencing leukocyte cell functions which can lead to inhibition of cancerous cell growth or proliferation thereof, and/or killing of cancerous cells harboured by a warm-blooded mammalian subject.
• Electromagnetic energy generating devices and use of electromagnetic energies for treating living mammalian subjects harbouring cancerous cells described in the literature include: U.S. Pat. No. 5,908,441 issued Jun. 1, 1999 to Bare; James E. and the references cited therein and so-called “NovoCure technology” involving in vivo implantation of electrodes to either side of tumorous growths. This literature however does not contemplate very low energy emissions of electromagnetic energy involving amplitude-modulated high frequency carrier signals as required in terms of the present invention.
• U.S. Pat. No. 5,690,692 issued on Nov. 25, 1997 entitled “Bio-Active Frequency Generator and Method” describes a programmable control which instructs a frequency synthesizer to enable generation of an electrical current at a specific precise frequency signal or at a series of specific precise frequencies signals having a square wave form to within an accuracy of 0.001 Hz. This Patent contemplates amplifying the voltage of the generated signals and applying the signals to a subject at the specific precise frequency or sequentially at the series of specific precise frequencies by means of electrodes held by or otherwise connected to the subject (which may be a mammal or a food). Once again, this Patent does not contemplate very low energy emissions involving amplitude-modulated high frequency carrier signals as required in terms of the present invention.
SUMMARY OF THE INVENTION
• In one aspect of the invention, an electronic system is provided which is activatable by electrical power. The system is employed to influence cellular functions or malfunctions in a warm-blooded mammalian subject. The system comprises one or more controllable low energy electromagnetic energy generator circuits for generating one or more high frequency radio frequency RF carrier signals. One or more microprocessors or integrated circuits comprising or communicating with the one or more generator circuits are provided which are also for receiving control information from a source of programmed control information. The one or more generator circuits include one or more amplitude modulation control signal generators for controlling amplitude modulated variations of the one or more high frequency carrier signals. The one or more generator circuits furthermore include one or more programmable amplitude modulation frequency control signal generators for controlling the frequency at which the amplitude modulations are generated. The one or more amplitude modulation frequency control generators are, in terms of an important improvement of the present invention, adapted to accurately control the frequency of the amplitude modulations to within an accuracy of at least 1000 ppm relative to one or more determined or predetermined reference amplitude modulation frequencies selected from within a range of 0.01 Hz to 150 kHz. The system furthermore comprises a connection or coupling position for connection or coupling to or being connected or coupled to an electrically conductive applicator for applying to the warm-blooded mammalian subject the one or more amplitude-modulated low energy emissions at said accurately controlled modulation frequencies.
• As used herein, the term, “accurately controlled” means that the modulated low energy electromagnetic emissions should be modulated to within a resolution of at most about 1 Hz of intended higher frequencies (greater than about 1000 Hz) determined or predetermined modulation frequencies. For example, if one of the one or more determined or predetermined modulation frequencies to be applied to the warm-blooded mammalian subject is about 2000 Hz, the accurate control should lead to such modulated low energy emission being generated at a frequency of between about 1999 and about 2001 Hz. However, and in terms of what has been determined from experiences in treating human subjects harbouring cancerous cells with the aim of arresting proliferation or killing of such cells, it is preferable that the accurate control should lead to a resolution of about 0.5, more preferably about 0.1, yet more preferably about 0.01 and indeed most preferably about 0.001 Hz of the intended determined or predetermined modulation frequency.
• Of importance is the requirement for emissions to be at a very low and safe energy level and result in low levels of absorption, the reason believed to be that physiological exchanges or flow of electrical impulses within warm-blooded animals (which are to be affected by application of the emissions of the present invention) are similarly at very low energy levels. In any event, in the region (at or near to the position of contact or close-by induction of the electrically conductive applicator with a subject receiving treatment), the specific absorption rate (SAR) should be and is most preferably substantially less than 1.6 milliW/g weight of living tissue.
• Furthermore of importance to achieve the intended biological therapeutic effect is that the stability of the emissions be maintained during emission, and that such stability should preferably be of the order of 10⁻⁵, more preferably 10⁻⁶, and most preferably 10⁻⁷, stability being determined as the relative deviation of frequency divided by the desired frequency, e.g. 0.01 Hz (deviation)/1,000 Hz (desired freq.)=10⁻⁵.
• As already described in said EP 0 592 851 B1, the system includes a microprocessor (which may more recently be replaced by an integrated circuit) into which control information is loaded from an application storage device. The microprocessor (or now alternatively integrated circuit) then controls the function of the system to produce the desired therapeutic emissions. Also described is the provision in the system of an impedance transformer connected intermediate the emitter of low energy electromagnetic emissions and a probe (here more broadly described as an electrically conductive applicator) for applying the emissions to the patient. The impedance transformer substantially matches the impedance of the patient seen from the emitter circuit with the impedance of the output of the emitter circuit.
BRIEF DESCRIPTION OF THE DRAWINGS
• FIG. 1 shows an exemplary casing structure for the electronic circuit shown in FIG. 2, an applicator 13 (exemplified as a probe suitable for being placed in the mouth of a patient) and an interface 16 (which may be replaced by a receiver) for receiving information from a source of information 52 such as may be comprised in an information storage device, e.g. of the nature described and illustrated in FIGS. 12 to 17 of EP 0 592 851 B1.
• FIG. 2 is a block diagram of exemplary circuitry which may be comprised in the exemplary casing structure of FIG. 1. This FIG. 2 differs essentially from FIG. 2 of EP 0 592 851 B1 by comprising a highly accurate modulation frequency generator 31 (named a Digital Direct Synthesizer or DDS), which enables accurate control of modulatable oscillator represented by dotted line block 106.
• Reference is made to the various Figures of EP 0 592 851 B1 and the detailed description thereof, a number of which are exemplary of components which may be comprised in the circuit of FIG. 2.
• Thus, FIG. 3 of EP 0 592 851 B1 is a detailed schematic of a modulation signal generator 31, replaced by a DDS modulation frequency generator 31 comprised in the circuit of present FIG. 2;
• FIG. 4 of EP 0 592 851 B1 is a detailed schematic of a modulation signal buffer and carrier oscillator circuit which may be employed in the circuit of the present FIG. 2;
• FIG. 5 of EP 0 592 851 B1 is a detailed schematic example of an amplitude modulation (AM) and power generator 34 and output filter 39 which could be comprised in the circuit of the present FIG. 2;
• FIG. 6 of EP 0 592 851 B1 is a detailed schematic example of an impedance transformer 14 which may be comprised in the circuit of the present FIG. 2;
• FIG. 7 of EP 0 592 851 B1 is a detailed schematic example of an emission sensor 53 which may be comprised in the circuit of the present FIG. 2;
• FIG. 8 of EP 0 592 851 B1 is a detailed schematic example of an output power sensor circuit 54 which may be employed in the circuit of the present FIG. 2.
• FIG. 9 of EP 0 592 851 B1 is a detailed schematic example of a display module or information output 17 which may be included in the circuit of the present FIG. 2.
• FIG. 10 of EP 0 592 851 B1 is a detailed schematic example of a power supply control circuit including battery charger 57 which may be comprised in the circuit of the present FIG. 2.
• FIGS. 11a-d of EP 0 592 851 B1 are exemplary flow charts of the method of operation of the system of FIGS. 1 and 2.
DETAILED DESCRIPTION
• Referring to FIG. 1, presented is a modulated low energy electromagnetic emission application system 11, in accordance with the present invention. As described in prior U.S. Pat. Nos. 4,649,935 and 4,765,322, such a system has proven to be useful in the practice of Low Energy Emission Therapy (LEET, a trademark of Symtonic S.A. or a successor of this Company), which involves application of emissions of low energy radio frequency (RF) electromagnetic waves to a warm-blooded mammalian subject. The application has proven to be an effective mode of treating a warm-blooded mammalian subject suffering from central nervous system (CNS) disorders such as, for example, generalized anxiety disorders, panic disorders, sleep disorders including insomnia, psychiatric disorders such as depression, obsessive compulsive disorders, disorders resulting from substance abuse, sociopathy, post traumatic stress disorders or other disorders of the central nervous system and combinations thereof.
• The system includes an electrically conductive applicator 12, 13 for applying one or more electromagnetic emissions to the warm-blooded mammalian subject. One form of applicator may consist of an electrically conductive probe or mouthpiece 13 which is inserted into the mouth of a subject undergoing treatment. Probe 13 is connected to an electromagnetic energy emitter (see also FIG. 2), through coaxial cable 12 and impedance matching transformer 14.
• It has previously been considered that an efficient connection of an electrically conductive applicator to a subject could only be achieved by means of a probe which is adapted to be applied to any mucosa of the subject, such as by being located within oral, nasal, optical, urethral, anal, and/or vaginal cavities or surfaces. It has however now been determined that in fact satisfactory application of emissions to a patient can be achieved by simpler physical contact of the electrically conductive applicator with the skin of the patient. Emissions to the patient may, for example be achieved by a conductive, inductive, capacitive or radiated coupling to the patient. An example of a coupling found to be effective involving indirect physical contact with the skin of a patient, is an insulated applicator to be placed over or within an ear of the patient. The emissions thus passed to the patient may be either by capacitive or radiated means or by a combination of both. An important advantage of a device which does not need to be placed in the mouth of a patient is that the patient is able to speak clearly during a time of treatment and can receive treatment during activities of daily living. The treatment is accordingly more user-friendly, can be administered for longer periods of time and can lead to enhanced patient compliance.
• Electronic system 11 also includes a connector or coupler for connection to a programmable device such as a computer or an interface or receiver 16 which is adapted to receive an application storage device 52 such as, for example, magnetic media, semiconductor media, optical media or mechanically encoded media, or programmed emissions programmed with control information employed to control the operation of system 11 so that the desired type of low energy emission therapy is applied to the patient.
• Application storage device 52 can be provided with a microprocessor which, when applied to interface 16, operates to control the function of system 11 to apply the desired low energy emission therapy. Alternatively, application storage device 52 can be provided with a microprocessor which is used in combination with microprocessor 21 within system 11. In such case, the microprocessor within device 52 could assist in the interfacing of storage device 52 with system 11, or could provide security checking functions.
• System 11 may also include a display 17 which can display various indications of the operation of system 11. In addition, system 11 may include on and off power buttons 18 and 19, optionally replaced by user interface 21A (refer to FIG. 2).
• Referring to FIG. 2, presented is a block diagram of exemplary electronic circuitry of system 11, in accordance with the present invention. A data processor, such as for example, microprocessor or integrated circuit 21, operates as the controller for electronic system 11, and is connected to control the various components of the system 11, for example, through address bus 22, data bus 23 and input/output lines 25. The block diagram of FIG. 2 is modified as compared to FIG. 2 of EP 0 592 851 B1 by including what is known as a digital direct synthesizer (DDS) 31 which operates as a accurate and stable modulation frequency generator within the system 11. An exemplary DDS device is available from Analog Devices of Norwood, Mass. 02062-9106, USA, Part No AD9835. The device is a numerically controlled oscillator and modulation capabilities are provided for phase modulation and frequency modulation. As represented by dotted line block 102, entitled “PROCESSOR WITH DAC”, the functionality of the DDS may also be combined with microprocessor 21 with digital to analogue converter (DAC).
• Microprocessor 21 preferably includes internal storage for the operation of a coded control program, and temporary data. In addition, microprocessor 21 may include input/output ports and internal timers. Microprocessor 21 may be a microcontroller, for example microcontrollers 8048 or 8051 available from Intel Corporation of Santa Clara, Calif. 95054-1549, USA.
• The timing for microprocessor 21 is provided by system clock oscillator 26A which may be run at any clock frequency suitable for the particular type of microprocessor used. An exemplary clock frequency is about 8.0 MHz. Oscillator 26A may be replaced by reference frequency oscillator 26 which secures the stability of the accurate modulation frequency. RF (radio frequency) oscillator 32 may also be employed for this purpose. A combination of oscillators is represented by dotted line block 104, entitled “OSCILLATOR”.
• An exemplary operating program for microprocessor 21 is presented in flow chart form with reference to FIGS. 11a-d of EP 0 592 851 B1. In general, microprocessor 21 functions to control controllable electromagnetic energy generator circuit 29 to produce a desired form of modulated low energy electromagnetic emission for application to a subject through applicator or probe 13.
• Dotted line block 29, entitled CONTROLLABLE GENERATOR, includes DDS modulation frequency generator 31 and carrier signal oscillator 32. Microprocessor 21 operates to activate or deactivate controllable generator circuit 29 through oscillator disable line 33, as described in greater detail in EP 0 592 851 B1. Controllable generator circuit 29 also includes an AM modulator and power generator 34 which operates to amplitude modulate a carrier signal produced by carrier oscillator 32 on carrier signal line 36, with a modulation signal produced by modulation signal generator circuit 31 on modulation signal line 37. The combination of the functionality of the DDS modulation frequency generator 31, with processor 21 with DAC, represented by dotted line block 102, enables output lines 33 and 37 to be combined to produce a single signal. The combination furthermore enables arbitrary or periodic wave forms of any shape to be generated, as similarly described in EP 0 592 851 B1.
• AM modulator and power generator 34 produces an amplitude modulated carrier signal on modulated carrier signal line 38, which is then applied to emitter output filter circuit 39. The filter circuit 39 is connected to probe or applicator 13 via power emission sensor 54, coaxial cable 12 and impedance transformer 14.
• Microprocessor 21 controls DDS modulation signal generator circuit 31 of controllable generator circuit 29 via interface lines 25.
• As is illustrated and described in EU 0 592 851 B1, microprocessor 21 may select a desired waveform stored in a modulation waveform storage device 43 and also controls a waveform address generator 41 to produce on waveform address bus 42 a sequence of addresses which are applied to modulation signal storage device 43 in order to retrieve the selected modulation signal. In the embodiment described in EP 0 592 851 B1, the desired modulation signal is retrieved from modulation signal storage device 43 and applied to modulation signal bus 44 in digital form. Modulation signal bus 44 is applied to wave form generator and DAC 46 which converts the digital modulation signal into analogue form. This analogue modulation signal is then applied to a selective filter 47 which, under control of microprocessor 21, filters the analogue modulation signal by use of a variable filter network including resistor 48 and capacitors 49 and 51 in order to smooth the wave form produced by DAC 46 on modulation signal line 20.
• A further embodiment possibility is a combination of PROCESSOR WITH DAC dotted line block 102 with OSCILLATOR dotted line block 104 or with a combination of oscillators 26 and 26A. With such a combination, the hardware solution described in EP 0 592 851 B1 can be realized internally in the processor 102 with multiple outputs 33 and 37 or a single output combining these signals.
• The above embodiment from EP 0 592 851 B1 is in part replaced by the functionality of the DDS modulation frequency modulator 31. However, if it is determined that emissions of different wave forms is desirable, it would be desirable to include the modulation signal storage device 43 and wave form generator 46 described in EP 0 592 851 B1. Various modulation signal wave forms may then be stored in modulation signal storage device 43. Wave forms that have been successfully employed include square wave forms or sinusoidal wave forms. Other possible modulation signal wave forms include rectified sinusoidal, triangular, or other wave forms and combinations of all of the above.
• The particular modulation control information employed by microprocessor 21 to control the operation of controllable generator circuit 29, is stored in application storage device 52. The application storage device is conveniently a computer comprising or being for receiving the information. Alternatively, application storage devices illustrated and described in EP 0 592 851 B1, with reference to FIGS. 12, 13, 14 and 15, may be selected.
• Interface 16 is configured as appropriate for the particular application storage device 52 in use. Interface 16 translates the control information stored in application storage device 52 into a usable form for storage within the memory of microprocessor 21 to enable microprocessor 21 to control controllable generator circuit 29 to produce the desired modulated low energy emission.
• Interface 16 may directly read the information stored on application storage device 52, or it may read the information through use of various known communication links. For example, radio frequency, microwave, laser, telephone, internet or optical based communications links may be employed to transfer information between interface or receiver 16 and application storage device or computer 52.
• The system 11 may comprise a user identification device, included in block 21 a in FIG. 2. Conveniently, such a device communicates with the one or more data processors or integrated circuits 21 via interface 16, as shown. The user identification device may be of any type, a finger print reader being an example. Such a reader is for example available from Lenovo, 70563 Stuttgart, Germany, Part No. 73P4774.
• The control information stored in application storage device or computer 52 specifies various controllable parameters of the modulated low energy RF electromagnetic emission to be applied to a subject through applicator or probe 13. Such controllable parameters include, for example, but are not necessarily limited to, the frequency and amplitude of the carrier, the amplitudes and frequencies and wave forms of the modulation of the carrier, the duration of the emission, the power level of the emission, the duty cycle of the emission (i.e., the ratio of on time to off time of pulsed emissions applied during a treatment), the sequence of application of different modulation frequencies for a particular application, and the total number of treatments and duration of each treatment prescribed for a particular subject, and combinations thereof.
• For example, the carrier signal and modulation signal may be selected to drive the applicator or probe 13 with an amplitude modulated signal in which the carrier signal includes spectral frequency components below about 1 GHz, and preferably between about 1 MHz and about 900 MHz, and in which the modulation signal comprises spectral frequency components between about 0.01 Hz and 150 KHz. The one or more modulation frequencies may be simultaneously emitted or sequenced to form the modulation signal.
• As an additional feature, an electromagnetic emission sensor 53 may be provided to detect the presence of electromagnetic emissions at the frequency of the carrier oscillator 32. Emission sensor 53 provides microprocessor 21 with an indication of whether or not electromagnetic emissions at the desired frequency are present. Microprocessor 21 then takes appropriate action, for example, by displaying an error message on display 17, disabling controllable generator circuit 29, or the like.
• A power sensor 54 is preferably included which detects the amount of power applied to the subject through applicator or probe 13 compared to the amount of power returned or reflected from the subject. This ratio is indicative of the proper use of the system during a therapeutic session. Power sensor 54 applies to microprocessor 21, through power sensor line 56, an indication of the amount of power applied to patient through applicator or probe 13 relative to the amount of power reflected from the patient.
• The indication provided on power sense line 56 may be digitalized and employed by microprocessor 21, for example, to detect and control a level of applied power, and to record on application storage device 52 information related to the actual treatments applied to and received by the patient. Such information may then be used by a physician or other clinician to assess patient treatment compliance and effect. Such treatment information may include, for example: the number of treatments applied for a given time period; the actual time and date of each treatment; the number of attempted treatments; the treatment compliance (i.e., whether the applicator or probe was in place or not during the treatment session); and the cumulative dose of a particular modulation frequency.
• The level of power applied is preferably controlled to cause the specific absorption rate (SAR) of energy absorbed by the patient to be from about 1 microWatt per kilogram of tissue to about 50 Watts per kilogram of tissue. Preferably, the power level is controlled to cause an SAR of from about 100 microWatts per kilogram of tissue to about 10 Watts per kilogram of tissue. Most preferably, the power level is controlled to cause an SAR of from about 1 milliWatt per kilogram of tissue to about 100 milliWatts per kilogram of tissue. These SARs may be in any tissue of the patient, but are preferably in the tissue of the central nervous system or the diseased tissue.
• System 11 may also include powering circuitry including battery and charger circuit 57 and battery voltage change detector 58.
• The RF carrier oscillator 32 produces a RF carrier frequency of about 27 MHz. Other embodiments of the invention contemplate RF carrier frequencies of about 48 MHz, about 433 MHz or about 900 MHz. In general, the RF carrier frequency produced by carrier oscillator 32 has spectral frequency components less than about 1 GHz and preferably between about 1 MHz and about 916 MHz. Although the described embodiment contemplates that once set, the carrier oscillator frequency remains substantially constant, the carrier frequency produced by carrier oscillator 32 may be variable and controllable by microprocessor 21 by use of stored or transmitted control information.
• Carrier oscillator 32 produces on carrier signal line 36 a carrier signal which is then modulated by the modulation signal carried on signal line 37.
• Oscillator disable line 33 enables microprocessor 21 to disable the signal from oscillator 32 by applying an appropriate disable signal to oscillator disable line 33.
• The output of the AM modulator and power generator 34 appears on signal line 38. This modulated signal is applied through emitter output filter 39 which substantially reduces or eliminates the carrier harmonics resulting from side effects of the modulator and power generator circuit 34.
• The output of the AM modulator and power generator 34 and emitter output filter 39 may be designed to possess a 50 Ohm output impedance to match a 50 Ohm impedance of coaxial cable 12.
• It has been determined through impedance measurements that when a probe 13 is applied within the mouth of a subject, the probe/subject combination exhibits a complex impedance of the order of about 150+j200 Ohms. Impedance transformer 14 serves to match this complex impedance with the 50 Ohm impedance of coaxial cable 12 and therefore the output impedance of the AM modulator 34 and output filter 39. This promotes power transmission, and minimizes reflections.
• The arrangement described above has been optimized for a contact probe with coupling to the mucosa of the mouth. In a further example, a conductive, isolated probe has been used at a frequency around 433 MHz coupling to the outer ear channel. Due to the different probe design in such a frequency band and with this coupling method, the values of matching elements (79 and 81 described in EP 0592 851 B1) would be different or could even be omitted. Applicator or probe 13 may then be regarded as a capacitive coupler or as an antenna matched to the capacitive load.
• As described in EP 0 592 851 B1, with reference to the flow charts of FIGS. 11a-d, microprocessor 21 may operate to analyse the signal appearing on power sense line 56 to determine and control the amount of power applied to the patient, and to assess patient treatment compliance, and possibly to record indicia of the patient treatment compliance on application storage device 52 for later analysis and assessment by a physician or other clinician.
• Exemplary of treatments performed on patients have included brain, bladder, colorectal, kidney, mesothelium, neuroendocrine, liver, lung, breast, ovary, pancreas, prostate and thyroid tumour types. The treatments involved applying an about 27.12 MHz RF signal, amplitude modulated at specifically defined frequencies ranging from about 0.2 to about 23,000 Hz at very high precision and stability. Further Examples of treatment modes (at specific accurately controlled AM frequencies) for specified types of tumours are described in detail below.
• The following are synopses of abstracts for future publications related to uses of electronic devices of the present invention:
A Example A A Phase I Study of Therapeutic Amplitude-Modulated Electromagnetic Fields (THERABIONIC) in Advanced Tumors
• Boris Pasche ¹, Alexandre Barbault ¹, Brad Bottger ², Fin Bomholt ³, Niels Kuster ⁴. ¹ Cabinet Médical de l'Avenue de la Gare 6, CH-1003-Lausanne, Switzerland.² Danbury Hospital, Danbury, Conn.-06810.³ SPEAG, Zurich, CH-8004-Zurich, Switzerland⁴ IT'IS Foundation, Swiss Federal Institute of Technology, Zurich, Switzerland.
• Background: In vitro studies suggest that low levels of amplitude-modulated electromagnetic fields may modify cell growth. Specific frequencies have been identified specific frequencies that may block cancer cell growth. A portable and programmable device capable of delivering low levels of amplitude-modulated electromagnetic fields has been developed. The device emits a 27.12 MHz radiofrequency signal, amplitude-modulated at cancer-specific frequencies ranging from 0.2 to 23,000 Hz with high precision. The device is connected to a spoon-like coupler, which is placed in the patient's mouth during treatment.
• Methods: A phase I study was conducted consisting of three daily 40 min treatments. From March 2004 to September 2006, 24 patients with advanced solid tumors were enrolled. The median age was 57.0±12.2 years. 16 patients were female. As of January 2007, 5 patients are still on therapy, 13 patients died of tumor progression, 2 patients are lost to follow-up and one patient withdrew consent. The most common tumor types were breast (7), ovary (5) and pancreas (3). 22 patients had received prior systemic therapy and 16 had documented tumor progression prior to study entry.
• Results: The median duration of therapy was 15.7±19.9 weeks (range: 0.4-72.0 weeks). There were no NCI grade 2, 3 or 4 toxicities. Three patients experienced grade 1 fatigue during and immediately after treatment. 12 patients reported severe pain prior to study entry. Two of them reported significant pain relief with the treatment. Objective response could be assessed in 13 patients, 6 of whom also had elevated tumor markers. 6 additional patients could only be assessed by tumor markers. Among patients with progressive disease at study entry, one had a partial response for >14.4 weeks associated with >50% decrease in CEA, CA 125 and CA 15-3 (previously untreated metastatic breast cancer); one patient had stable disease for 34.6 weeks (add info); one patient had a 50% decrease in CA 19-9 for 12.4 weeks (recurrent pancreatic cancer). Among patients with stable disease at enrollment, four patients maintained stable disease for 17.0, >19.4, 30.4 and >63.4 weeks.
• Conclusions: The treatment is a safe and promising novel treatment modality for advanced cancer. A phase II study and molecular studies are ongoing to confirm those results.
Example B A Phase II Study of Therapeutic Amplitude-Modulated Electromagnetic Fields (THERABIONIC) in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
• Frederico P Costa ¹, Andre Cosme de Oliveira ¹, Roberto Meirelles Jr ¹, Rodrigo Surjan ¹, Tatiana Zanesco ¹, Maria Cristina Chammas ¹, Alexandre Barbault ², Boris Pasche ². ¹ Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil. ²Cabinet Médical Avenue de la Gare 6, CH-1003-Lausanne, Switzerland
• Background: Phase I data suggest that low levels of electromagnetic fields amplitude-modulated at specific frequencies administered intrabucally with the device of Example A are a safe and potentially effective treatment for advanced cancer. The device emits a 27.12 MHz RF signal, amplitude-modulated with cancer-specific frequencies ranging from 0.2 to 23,000 Hz with high precision. The device is connected to a spoon-like coupler placed in the patient's mouth during treatment. Patients with advanced hepatocellular carcinoma HCC and limited therapeutic options were offered treatment with a combination of HCC-specific frequencies.
• Methods: From October 2005 to October 2006, 38 patients with advanced HCC were recruited in a phase II study. The patients received three daily 40 min treatments until disease progression or death. The median age was 64.0±14.2 years. 32 patients were male and 29 patients had documented progression of disease (POD) prior to study entry.
• Results: As of January 2007, 12 patients are still on therapy, 20 patients died of tumor progression, 2 patients are lost to follow-up and 3 patients withdrew consent. 27 patients are eligible for response. The overall objective response rate as defined by partial response (PR) or stable disease (SD) in patients with documented POD at study entry was 31.6%: 3 PR and 9 SD. The median survival was 20.7 weeks with a median duration of therapy of 17.5 weeks. 13 patients have received therapy for more than six months. The median duration of response is 12.9 weeks. 12 patients reported pain at study entry: 8 of them (66%) experienced decreased pain during treatment. There were no NCI grade 2/3/4 toxicities. One patient developed grade 1 mucositis and grade 1 fatigue.

• Patient characteristics (n = 38)

  Cirrhosis	36
  Portal vein thrombosis	9
  Elevated AFP	25
  Extra-hepatic metastases	12
  Previous intrahepatic/systemic therapy	30
  Previous hepatic resection/RFA or	8
  ethanol

  CLIP	0/1:	12	>2:	22
  Okuda	I:	14	II/III:	20
  Child-Pugh	A:	15	B:	19
  MELD	Median:	10

• Conclusion: In patients with advanced HCC the treatment is a safe and effective novel therapeutic option, which has antitumor effect and provides pain relief in the majority of patients.
• Thus, it is seen that the electronic device of the present invention, comprising means for the accurate control over the frequencies and stability of amplitude modulations of a high frequency carrier signal, provides a safe and promising novel treatment modality for the treatment of patients suffering from various types of advanced forms of cancer.
• Exemplary of above accurately controlled amplitude modulated frequencies controlling the frequency of amplitude modulations of a high frequency carrier signal are set forth below along with the type of cancer or tumour harboured by a subject to be treated.
Example 1 AM Frequencies Employed for Treatment of Breast Cancer (188 Frequencies so Far Included)

• 78.76 Hz
  181.821 Hz
  414.817 Hz
  440.933 Hz
  628.431 Hz
  721.313 Hz
  813.205 Hz
  818.342 Hz
  891.901 Hz
  929.095 Hz
  929.1 Hz
  1021 Hz
  1372.207 Hz
  1372.934 Hz
  1588.721 Hz
  1670.699 Hz
  1821.729 Hz
  1836.219 Hz
  2193.937 Hz
  2221.323 Hz
  2278.312 Hz
  2357.832 Hz
  2381.443 Hz
  2417.323 Hz
  2431.334 Hz
  2450.332 Hz
  2551.313 Hz
  2556.221 Hz
  2598.853 Hz
  2621.322 Hz
  2740.191 Hz
  2851.347 Hz
  2885.322 Hz
  2919.273 Hz
  3074.333 Hz
  3115.188 Hz
  3249.529 Hz
  3405.182 Hz
  3432.274 Hz
  3434.693 Hz
  3594.231 Hz
  3647.619 Hz
  3742.957 Hz
  3753.382 Hz
  3830.732 Hz
  3855.823 Hz
  3916.321 Hz
  3935.218 Hz
  3975.383 Hz
  3993.437 Hz
  4153.192 Hz
  4194.968 Hz
  4241.321 Hz
  4243.393 Hz
  4253.432 Hz
  4314.444 Hz
  4318.222 Hz
  4375.962 Hz
  4393.419 Hz
  4417.243 Hz
  4481.463 Hz
  4482.223 Hz
  4495.138 Hz
  4549.808 Hz
  4558.306 Hz
  4779.451 Hz
  4838.674 Hz
  4871.513 Hz
  4895.296 Hz
  4962.213 Hz
  4969.224 Hz
  4979.321 Hz
  5027.231 Hz
  5059.792 Hz
  5118.094 Hz
  5176.287 Hz
  5365.222 Hz
  5376.392 Hz
  5426.323 Hz
  5431.542 Hz
  5521.621 Hz
  5739.422 Hz
  5745.218 Hz
  5821.975 Hz
  6037.432 Hz
  6044.333 Hz
  6086.256 Hz
  6208.932 Hz
  6212.808 Hz
  6231.031 Hz
  6280.321 Hz
  6329.391 Hz
  6476.896 Hz
  6497.319 Hz
  6504.983 Hz
  6651.276 Hz
  6757.901 Hz
  6758.321 Hz
  6855.286 Hz
  6858.121 Hz
  6898.489 Hz
  7092.219 Hz
  7120.218 Hz
  7127.311 Hz
  7156.489 Hz
  7208.821 Hz
  7282.169 Hz
  7376.329 Hz
  7488.742 Hz
  7541.319 Hz
  7577.421 Hz
  7621.085 Hz
  7627.207 Hz
  7650.939 Hz
  7691.212 Hz
  7842.184 Hz
  7849.231 Hz
  7915.423 Hz
  7932.482 Hz
  7949.196 Hz
  7967.311 Hz
  8021.229 Hz
  8070.181 Hz
  8114.032 Hz
  8149.922 Hz
  8194.19 Hz
  8245.801 Hz
  8328.322 Hz
  8330.534 Hz
  8355.987 Hz
  8408.121 Hz
  8431.184 Hz
  8452.119 Hz
  8548.324 Hz
  8749.383 Hz
  8782.421 Hz
  8784.424 Hz
  8923.1 Hz
  8923.361 Hz
  8935.752 Hz
  8936.1 Hz
  9012.282 Hz
  9012.896 Hz
  9060.323 Hz
  9072.409 Hz
  9131.419 Hz
  9199.232 Hz
  9245.927 Hz
  9270.322 Hz
  9279.193 Hz
  9393.946 Hz
  10227.242 Hz
  10340.509 Hz
  10363.313 Hz
  10449.323 Hz
  10456.383 Hz
  10468.231 Hz
  10470.456 Hz
  10472.291 Hz
  10689.339 Hz
  10832.222 Hz
  11525.121 Hz
  11541.915 Hz
  11812.328 Hz
  11812.419 Hz
  11840.323 Hz
  11925.089 Hz
  12123.281 Hz
  12267.281 Hz
  12294.283 Hz
  12611.288 Hz
  12629.222 Hz
  12633.372 Hz
  12648.221 Hz
  13315.335 Hz
  13331.358 Hz
  13735.241 Hz
  13826.325 Hz
  13853.232 Hz
  13990.123 Hz
  14122.942 Hz
  14162.332 Hz
  14519.232 Hz
  14543.128 Hz
  15651.323 Hz
  17352.085 Hz
  18785.463 Hz
  30182.932 Hz

Example 2 AM Frequencies Employed for Treatment of Liver Cancer (162 Frequencies so Far Included)

• 423.321 Hz
  427.062 Hz
  470.181 Hz
  560.32 Hz
  642.932 Hz
  668.209 Hz
  677.972 Hz
  811.924 Hz
  842.311 Hz
  843.22 Hz
  1250.504 Hz
  1755.402 Hz
  1873.477 Hz
  1924.702 Hz
  1975.196 Hz
  2017.962 Hz
  2083.419 Hz
  2190.731 Hz
  2221.323 Hz
  2324.393 Hz
  2353.478 Hz
  2362.309 Hz
  2419.309 Hz
  2425.222 Hz
  2430.219 Hz
  2431.094 Hz
  2471.328 Hz
  2478.331 Hz
  2743.995 Hz
  2744.211 Hz
  2831.951 Hz
  2843.283 Hz
  2859.891 Hz
  2873.542 Hz
  2886.232 Hz
  3042.012 Hz
  3078.983 Hz
  3086.443 Hz
  3127.232 Hz
  3160.942 Hz
  3206.315 Hz
  3267.433 Hz
  3269.321 Hz
  3457.291 Hz
  3505.229 Hz
  3516.296 Hz
  3531.296 Hz
  3546.323 Hz
  3572.106 Hz
  3576.189 Hz
  3669.513 Hz
  3923.221 Hz
  4013.932 Hz
  4071.121 Hz
  4079.951 Hz
  4222.821 Hz
  4238.402 Hz
  4256.321 Hz
  4289.296 Hz
  4312.947 Hz
  4435.219 Hz
  4471.188 Hz
  4483.889 Hz
  4486.384 Hz
  4629.941 Hz
  4732.211 Hz
  4876.218 Hz
  5086.281 Hz
  5124.084 Hz
  5133.121 Hz
  5247.142 Hz
  5270.834 Hz
  5340.497 Hz
  5520.218 Hz
  5882.292 Hz
  5926.512 Hz
  6037.311 Hz
  6180.334 Hz
  6329.195 Hz
  6350.333 Hz
  6361.321 Hz
  6364.928 Hz
  6383.321 Hz
  6461.175 Hz
  6733.331 Hz
  6758.232 Hz
  6779.482 Hz
  6856.222 Hz
  6877.183 Hz
  6980.525 Hz
  7019.235 Hz
  7043.209 Hz
  7130.323 Hz
  7144.142 Hz
  7210.223 Hz
  7291.21 Hz
  7510.92 Hz
  7529.233 Hz
  7549.212 Hz
  7650.028 Hz
  7680.518 Hz
  7692.522 Hz
  7829.231 Hz
  7862.209 Hz
  7947.392 Hz
  7979.308 Hz
  8028.339 Hz
  8055.942 Hz
  8072.134 Hz
  8141.174 Hz
  8336.383 Hz
  8432.181 Hz
  8452.119 Hz
  8460.944 Hz
  8475.221 Hz
  8492.193 Hz
  8542.311 Hz
  8818.104 Hz
  8852.329 Hz
  8853.444 Hz
  8858.179 Hz
  8939.212 Hz
  9332.397 Hz
  9381.221 Hz
  9740.219 Hz
  9768.331 Hz
  9797.294 Hz
  10317.499 Hz
  10443.311 Hz
  10456.383 Hz
  10579.425 Hz
  10863.209 Hz
  10866.382 Hz
  11067.418 Hz
  11149.935 Hz
  11163.895 Hz
  11802.821 Hz
  11953.424 Hz
  12223.329 Hz
  12265.295 Hz
  12267.233 Hz
  12623.191 Hz
  12685.231 Hz
  12721.423 Hz
  12785.342 Hz
  14085.222 Hz
  14333.209 Hz
  14537.331 Hz
  14542.432 Hz
  14655.03 Hz
  14828.234 Hz
  15149.213 Hz
  15237.489 Hz
  16110.932 Hz
  16144.343 Hz
  18265.238 Hz
  18283.323 Hz
  18863.292 Hz
  18930.995 Hz
  19970.311 Hz
  20330.294 Hz
  20365.284 Hz

Example 3 AM Frequencies Employed for Treatment of Ovarian Cancer (273 Frequencies so Far Included)

• 78.76	Hz
  181.821	Hz
  410.245	Hz
  414.817	Hz
  436.332	Hz
  447.942	Hz
  481.191	Hz
  489.292	Hz
  559.292	Hz
  608.321	Hz
  655.435	Hz
  657.397	Hz
  657.483	Hz
  664.211	Hz
  708.8	Hz
  708.822	Hz
  734.921	Hz
  749.221	Hz
  764.232	Hz
  778.295	Hz
  779.403	Hz
  806.021	Hz
  806.389	Hz
  809.313	Hz
  824.327	Hz
  825.145	Hz
  835.129	Hz
  839.521	Hz
  841.208	Hz
  843.312	Hz
  956.984	Hz
  958.929	Hz
  985.313	Hz
  1024.208	Hz
  1102.635	Hz
  1121.329	Hz
  1159.738	Hz
  1372.207	Hz
  1396.498	Hz
  1502.181	Hz
  1518.208	Hz
  1552.123	Hz
  1579.212	Hz
  1624.802	Hz
  1670.699	Hz
  1696.403	Hz
  1762.938	Hz
  1771.402	Hz
  1775.313	Hz
  1821.729	Hz
  2016.323	Hz
  2034.231	Hz
  2050.282	Hz
  2053.396	Hz
  2082.234	Hz
  2089.092	Hz
  2221.323	Hz
  2228.832	Hz
  2253.704	Hz
  2254.329	Hz
  2278.312	Hz
  2332.949	Hz
  2348.233	Hz
  2381.443	Hz
  2413.193	Hz
  2425.222	Hz
  2433.321	Hz
  2439.253	Hz
  2465.23	Hz
  2477.919	Hz
  2669.177	Hz
  2715.232	Hz
  2733.843	Hz
  2802.339	Hz
  2812.321	Hz
  2831.386	Hz
  2835.332	Hz
  2851.347	Hz
  2877.192	Hz
  2885.322	Hz
  2887.385	Hz
  2894.972	Hz
  2973.771	Hz
  3080.592	Hz
  3157.483	Hz
  3161.465	Hz
  3223.232	Hz
  3238.148	Hz
  3249.529	Hz
  3262.145	Hz
  3314.321	Hz
  3361.671	Hz
  3366.311	Hz
  3523.215	Hz
  3527.233	Hz
  3542.213	Hz
  3590.376	Hz
  3629.232	Hz
  3632.793	Hz
  3636.289	Hz
  3637.085	Hz
  3669.513	Hz
  3770.189	Hz
  3858.916	Hz
  3919.232	Hz
  3957.185	Hz
  3975.228	Hz
  4061.131	Hz
  4072.322	Hz
  4169.451	Hz
  4174.259	Hz
  4241.321	Hz
  4243.393	Hz
  4261.228	Hz
  4279.113	Hz
  4309.335	Hz
  4314.188	Hz
  4318.222	Hz
  4328.928	Hz
  4380.321	Hz
  4394.134	Hz
  4412.252	Hz
  4424.236	Hz
  4439.341	Hz
  4442.161	Hz
  4447.221	Hz
  4458.339	Hz
  4556.322	Hz
  4566.009	Hz
  4682.643	Hz
  4718.331	Hz
  4749.302	Hz
  4765.331	Hz
  4917.202	Hz
  5011.325	Hz
  5149.331	Hz
  5228.172	Hz
  5237.132	Hz
  5313.353	Hz
  5745.218	Hz
  5757.897	Hz
  5762.386	Hz
  5812.322	Hz
  5869.321	Hz
  5882.292	Hz
  5921.249	Hz
  5991.932	Hz
  6069.458	Hz
  6071.319	Hz
  6083.214	Hz
  6161.782	Hz
  6169.341	Hz
  6275.232	Hz
  6294.929	Hz
  6350.333	Hz
  6406.891	Hz
  6407.207	Hz
  6450.787	Hz
  6477.098	Hz
  6477.929	Hz
  6478.338	Hz
  6543.421	Hz
  6552.24	Hz
  6663.955	Hz
  6753.338	Hz
  6851.323	Hz
  6855.286	Hz
  6875.232	Hz
  6882.949	Hz
  7206.403	Hz
  7232.214	Hz
  7257.489	Hz
  7276.209	Hz
  7281.219	Hz
  7285.693	Hz
  7429.212	Hz
  7460.932	Hz
  7480.228	Hz
  7495.763	Hz
  7539.432	Hz
  7564.185	Hz
  7650.028	Hz
  7689.728	Hz
  7780.294	Hz
  8021.921	Hz
  8038.961	Hz
  8040.322	Hz
  8044.233	Hz
  8095.313	Hz
  8143.491	Hz
  8164.332	Hz
  8261.121	Hz
  8302.285	Hz
  8309.752	Hz
  8372.532	Hz
  8408.121	Hz
  8424.229	Hz
  8428.313	Hz
  8435.451	Hz
  8486.421	Hz
  8492.797	Hz
  8548.324	Hz
  8554.361	Hz
  8562.965	Hz
  8579.323	Hz
  8579.333	Hz
  8642.181	Hz
  8655.818	Hz
  8758.341	Hz
  8779.323	Hz
  8792.231	Hz
  8819.127	Hz
  8831.132	Hz
  9028.031	Hz
  9173.264	Hz
  9184.338	Hz
  9186.919	Hz
  9393.946	Hz
  9482.409	Hz
  9737.211	Hz
  9746.232	Hz
  9922.231	Hz
  10032.684	Hz
  10446.028	Hz
  10478.221	Hz
  10545.313	Hz
  10639.345	Hz
  10743.118	Hz
  10813.981	Hz
  10832.421	Hz
  10838.243	Hz
  10862.429	Hz
  10865.127	Hz
  10917.229	Hz
  10977.188	Hz
  11120.209	Hz
  11177.289	Hz
  11177.409	Hz
  11321.491	Hz
  11359.093	Hz
  11673.031	Hz
  11793.886	Hz
  11895.229	Hz
  12074.531	Hz
  12216.212	Hz
  12253.329	Hz
  12260.933	Hz
  12262.853	Hz
  12292.222	Hz
  12357.353	Hz
  12527.032	Hz
  12755.333	Hz
  12947.311	Hz
  13717.221	Hz
  13825.295	Hz
  13829.195	Hz
  14410.949	Hz
  14436.201	Hz
  14537.218	Hz
  14947.184	Hz
  15429.139	Hz
  15443.309	Hz
  15450.183	Hz
  16144.343	Hz
  17932.432	Hz
  17951.395	Hz
  17970.122	Hz
  18337.222	Hz
  18378.321	Hz
  18921.415	Hz
  18926.951	Hz
  18931.327	Hz
  114508.332	Hz

Example 4 AM Frequencies Employed for Treatment of Prostate Cancer (183 Frequencies so Far Included)

• 331.3 Hz
  331.358 Hz
  403.218 Hz
  461.233 Hz
  522.2 Hz
  522.213 Hz
  618.4 Hz
  618.407 Hz
  618.8 Hz
  656.295 Hz
  657.394 Hz
  657.397 Hz
  657.4 Hz
  657.483 Hz
  659.033 Hz
  694.4 Hz
  694.689 Hz
  694.7 Hz
  741.4 Hz
  741.421 Hz
  749.221 Hz
  752.9 Hz
  752.933 Hz
  776.194 Hz
  785.219 Hz
  786.332 Hz
  793.331 Hz
  809.205 Hz
  819.322 Hz
  844.8 Hz
  844.822 Hz
  847.332 Hz
  1083.309 Hz
  1102.635 Hz
  1102.71 Hz
  1240.336 Hz
  1372.934 Hz
  1444.288 Hz
  1486.322 Hz
  1563.332 Hz
  1591.322 Hz
  1670.699 Hz
  1697.321 Hz
  1743.521 Hz
  2031.448 Hz
  2050.282 Hz
  2076.519 Hz
  2156.332 Hz
  2229.515 Hz
  2243.121 Hz
  2381.443 Hz
  2440.489 Hz
  2475.912 Hz
  2477.919 Hz
  2628.324 Hz
  2669.328 Hz
  2824.832 Hz
  2887.829 Hz
  2891.331 Hz
  3081.523 Hz
  3249.529 Hz
  3250.125 Hz
  3251.815 Hz
  3264.827 Hz
  3278.329 Hz
  3281.432 Hz
  3348.783 Hz
  3519.118 Hz
  3539.962 Hz
  3551.318 Hz
  3556.439 Hz
  3572.321 Hz
  3670.129 Hz
  3681.341 Hz
  3686.021 Hz
  3753.382 Hz
  3774.923 Hz
  3867.692 Hz
  3909.333 Hz
  3916.321 Hz
  4031.233 Hz
  4031.933 Hz
  4038.203 Hz
  4081.743 Hz
  4084.319 Hz
  4139.322 Hz
  4153.192 Hz
  4223.795 Hz
  4231.221 Hz
  4241.321 Hz
  4320.513 Hz
  4329.152 Hz
  4380.321 Hz
  4417.312 Hz
  4489.452 Hz
  4549.808 Hz
  4558.306 Hz
  4638.293 Hz
  4740.322 Hz
  4854.318 Hz
  4882.322 Hz
  4978.822 Hz
  5237.152 Hz
  5264.222 Hz
  5289.195 Hz
  5426.323 Hz
  5431.542 Hz
  5455.593 Hz
  6345.332 Hz
  6347.433 Hz
  6363.284 Hz
  6418.331 Hz
  6496.231 Hz
  6538.295 Hz
  6577.421 Hz
  6590.328 Hz
  6651.276 Hz
  6706.431 Hz
  6743.322 Hz
  6783.282 Hz
  6850.197 Hz
  6855.286 Hz
  6864.896 Hz
  6871.943 Hz
  6973.393 Hz
  7120.932 Hz
  7146.509 Hz
  7192.505 Hz
  7251.309 Hz
  7251.322 Hz
  7278.124 Hz
  7279.335 Hz
  7299.119 Hz
  7527.229 Hz
  7589.925 Hz
  7699.193 Hz
  7842.184 Hz
  8023.32 Hz
  8096.939 Hz
  8245.801 Hz
  8315.291 Hz
  8357.305 Hz
  8408.121 Hz
  8432.209 Hz
  8535.238 Hz
  8552.431 Hz
  8585.224 Hz
  8935.752 Hz
  9015.253 Hz
  9018.233 Hz
  9068.231 Hz
  9137.232 Hz
  9156.321 Hz
  9351.931 Hz
  9393.946 Hz
  9694.179 Hz
  9984.405 Hz
  10226.223 Hz
  10390.232 Hz
  10514.768 Hz
  10689.339 Hz
  10772.419 Hz
  10818.452 Hz
  11165.239 Hz
  11985.353 Hz
  12209.329 Hz
  12308.321 Hz
  12583.339 Hz
  13820.329 Hz
  14013.123 Hz
  14171.434 Hz
  14681.329 Hz
  14759.131 Hz
  14986.794 Hz
  15930.249 Hz
  16026.623 Hz
  17880.954 Hz
  18247.532 Hz
  18282.211 Hz
  18629.328 Hz
  19469.318 Hz
  19766.218 Hz
  60317.352 Hz

Example 5 AM Frequencies Employed for Treatment of Kidney Cancer (36 Frequencies so Far Included)

• 628.321 Hz
  631.141 Hz
  643.312 Hz
  812.512 Hz
  826.321 Hz
  1372.934 Hz
  2082.241 Hz
  2156.931 Hz
  2254.329 Hz
  3555.209 Hz
  3928.343 Hz
  4420.932 Hz
  4819.228 Hz
  4828.321 Hz
  5314.322 Hz
  6007.332 Hz
  7054.279 Hz
  7074.429 Hz
  7254.343 Hz
  8041.289 Hz
  8727.224 Hz
  8760.983 Hz
  8831.132 Hz
  8870.228 Hz
  10565.321 Hz
  10586.229 Hz
  10634.293 Hz
  10687.949 Hz
  11421.933 Hz
  11523.212 Hz
  11561.221 Hz
  11846.212 Hz
  12631.331 Hz
  12693.272 Hz
  14411.321 Hz
  20178.941 Hz

Example 6 AM Frequencies Employed for Treatment of Thyroid Cancer (110 Frequencies so Far Included)

• 493.442 Hz
  517.202 Hz
  618.927 Hz
  621.321 Hz
  648.252 Hz
  663.407 Hz
  821.202 Hz
  874.341 Hz
  914.429 Hz
  941.311 Hz
  983.429 Hz
  1587.811 Hz
  1723.389 Hz
  2179.231 Hz
  2315.888 Hz
  2341.312 Hz
  2445.123 Hz
  2454.232 Hz
  2723.302 Hz
  2740.384 Hz
  2749.323 Hz
  2856.253 Hz
  2859.495 Hz
  2886.232 Hz
  3021.122 Hz
  3078.275 Hz
  3080.592 Hz
  3198.323 Hz
  3248.321 Hz
  3271.329 Hz
  3284.192 Hz
  3335.332 Hz
  3434.911 Hz
  3440.212 Hz
  3475.216 Hz
  3509.522 Hz
  3533.328 Hz
  3637.085 Hz
  3682.489 Hz
  4154.301 Hz
  4243.393 Hz
  4261.228 Hz
  4330.289 Hz
  4340.833 Hz
  4358.333 Hz
  4366.294 Hz
  4426.387 Hz
  4458.339 Hz
  4479.113 Hz
  4744.424 Hz
  4865.421 Hz
  5323.192 Hz
  5324.123 Hz
  5548.879 Hz
  5711.283 Hz
  5754.332 Hz
  6455.131 Hz
  6620.132 Hz
  6666.839 Hz
  6714.189 Hz
  6745.333 Hz
  6766.281 Hz
  6884.432 Hz
  7036.122 Hz
  7230.838 Hz
  7323.209 Hz
  7355.378 Hz
  7432.143 Hz
  7534.221 Hz
  7623.184 Hz
  7725.339 Hz
  7920.879 Hz
  8013.953 Hz
  8019.912 Hz
  8040.231 Hz
  8078.955 Hz
  8082.173 Hz
  8147.1 Hz
  8281.259 Hz
  8309.752 Hz
  8311.371 Hz
  8435.094 Hz
  8525.789 Hz
  8744.527 Hz
  9009.329 Hz
  9070.809 Hz
  10020.521 Hz
  10039.109 Hz
  10127.279 Hz
  10134.161 Hz
  10257.324 Hz
  10498.339 Hz
  11537.292 Hz
  11559.292 Hz
  11913.222 Hz
  11927.934 Hz
  11955.949 Hz
  12120.049 Hz
  12139.222 Hz
  13636.082 Hz
  13654.272 Hz
  13677.211 Hz
  14014.941 Hz
  14445.214 Hz
  16023.119 Hz
  16048.391 Hz
  17323.196 Hz
  17577.221 Hz
  17881.709 Hz
  17911.323 Hz

Example 7 AM Frequencies Employed for Treatment of Bladder Cancer (28 Frequencies so Far Included)

• 623.243 Hz
  757.084 Hz
  870.4 Hz
  2454.423 Hz
  2480.191 Hz
  2581.101 Hz
  2715.232 Hz
  3042.012 Hz
  3196.194 Hz
  3265.323 Hz
  3438.109 Hz
  3692.319 Hz
  3952.308 Hz
  5230.227 Hz
  6022.942 Hz
  6061.711 Hz
  6710.899 Hz
  6721.912 Hz
  7181.784 Hz
  7458.209 Hz
  8235.21 Hz
  8749.232 Hz
  9354.812 Hz
  12532.729 Hz
  13467.209 Hz
  13777.9 Hz
  14015.241 Hz
  18524.419 Hz

Example 8 AM Frequencies Employed For Treatment of Colon Cancer (100 Frequencies so Far Included)

• 78.76 Hz
  796.562 Hz
  841.541 Hz
  842.783 Hz
  914.429 Hz
  1162.117 Hz
  1372.207 Hz
  1372.934 Hz
  1718.532 Hz
  2243.169 Hz
  2278.312 Hz
  2286.5 Hz
  2286.519 Hz
  2334.178 Hz
  2423.292 Hz
  2454.423 Hz
  2464.229 Hz
  2598.853 Hz
  2623.048 Hz
  3131.123 Hz
  3161.465 Hz
  3175.313 Hz
  3249.529 Hz
  3363.229 Hz
  3373.892 Hz
  3390.925 Hz
  3409.179 Hz
  3432.274 Hz
  3509.522 Hz
  3531.422 Hz
  3533.328 Hz
  3766.296 Hz
  4040.839 Hz
  4081.022 Hz
  4123.953 Hz
  4146.274 Hz
  4233.822 Hz
  4282.332 Hz
  4318.222 Hz
  4344.082 Hz
  4416.221 Hz
  4481.242 Hz
  4724.263 Hz
  4751.319 Hz
  4755.323 Hz
  4788.485 Hz
  5149.331 Hz
  5217.402 Hz
  5386.212 Hz
  5407.192 Hz
  5426.323 Hz
  5496.434 Hz
  5555.212 Hz
  5572.032 Hz
  5634.933 Hz
  5724.231 Hz
  5758.378 Hz
  5787.342 Hz
  5948.897 Hz
  5967.448 Hz
  5976.825 Hz
  6182.322 Hz
  6292.379 Hz
  6324.493 Hz
  6341.248 Hz
  6471.322 Hz
  6477.218 Hz
  6558.342 Hz
  6855.286 Hz
  7129.843 Hz
  7140.187 Hz
  7162.422 Hz
  7368.222 Hz
  7645.859 Hz
  7829.234 Hz
  7866.229 Hz
  7877.334 Hz
  8013.314 Hz
  8374.942 Hz
  8384.228 Hz
  8408.121 Hz
  8534.111 Hz
  8568.033 Hz
  8573.122 Hz
  9226.222 Hz
  9351.9 Hz
  9737.211 Hz
  9744.193 Hz
  9942.321 Hz
  10301.371 Hz
  10401.515 Hz
  10872.693 Hz
  11220.222 Hz
  11283.378 Hz
  12256.432 Hz
  13749.858 Hz
  15231.548 Hz
  15248.324 Hz
  58191.928 Hz
  60317.352 Hz

Example 9 AM Frequencies Employed for Treatment of Pancreas Cancer (166 Frequencies so Far Included)

• 331.3 Hz
  331.365 Hz
  436.3 Hz
  436.332 Hz
  447.942 Hz
  476.127 Hz
  559.292 Hz
  589.187 Hz
  624.218 Hz
  727 Hz
  734.921 Hz
  809.313 Hz
  845.309 Hz
  870.4 Hz
  963.221 Hz
  1156.79 Hz
  1157 Hz
  1179 Hz
  1360.133 Hz
  1372.207 Hz
  1372.934 Hz
  1804.126 Hz
  1816.221 Hz
  1873.477 Hz
  1967.211 Hz
  1990.482 Hz
  2278.312 Hz
  2315.921 Hz
  2320.315 Hz
  2334.178 Hz
  2381.443 Hz
  2469 Hz
  2477.919 Hz
  2542.221 Hz
  2598.853 Hz
  2647.938 Hz
  2685.081 Hz
  2716.095 Hz
  2721.331 Hz
  2732.231 Hz
  2809.849 Hz
  2823.428 Hz
  2835.332 Hz
  3134.313 Hz
  3241.461 Hz
  3255.219 Hz
  3263.432 Hz
  3286.255 Hz
  3330.935 Hz
  3373.892 Hz
  3438.109 Hz
  3449.219 Hz
  3535.219 Hz
  3549.215 Hz
  3564.419 Hz
  3619.412 Hz
  3622.312 Hz
  3638.432 Hz
  3696.424 Hz
  3943.214 Hz
  3976.929 Hz
  4014.889 Hz
  4041.219 Hz
  4044.195 Hz
  4056.384 Hz
  4085.971 Hz
  4144.592 Hz
  4153.192 Hz
  4161.889 Hz
  4243.393 Hz
  4332.498 Hz
  4341.423 Hz
  4355.327 Hz
  4417.885 Hz
  4422.322 Hz
  4451.297 Hz
  4486.384 Hz
  4558.306 Hz
  4580 Hz
  4685.082 Hz
  4839.589 Hz
  5151.402 Hz
  5209.911 Hz
  5262.282 Hz
  5271.312 Hz
  5387.73 Hz
  5494.928 Hz
  5521.221 Hz
  5573.209 Hz
  5609.382 Hz
  5929.616 Hz
  5948.897 Hz
  5966.112 Hz
  5976.825 Hz
  6064.197 Hz
  6086.256 Hz
  6157.253 Hz
  6215.298 Hz
  6333.917 Hz
  6365.242 Hz
  6558.342 Hz
  6568.278 Hz
  6823.194 Hz
  6853.391 Hz
  6855.286 Hz
  7213.204 Hz
  7228.528 Hz
  7238.232 Hz
  7277.921 Hz
  7280.422 Hz
  7320.494 Hz
  7366.412 Hz
  7534.221 Hz
  7548.713 Hz
  7567.127 Hz
  7620.851 Hz
  7663.209 Hz
  7725.203 Hz
  7852.233 Hz
  7920.879 Hz
  7985.122 Hz
  8008.323 Hz
  8013.312 Hz
  8045.484 Hz
  8242.332 Hz
  8351.622 Hz
  8408.121 Hz
  8455.894 Hz
  8551.231 Hz
  8743.321 Hz
  8789.631 Hz
  8868.809 Hz
  9012.241 Hz
  9028.994 Hz
  9131.232 Hz
  9658.296 Hz
  9663.495 Hz
  9680.737 Hz
  9824.442 Hz
  9942.321 Hz
  10279.122 Hz
  10388.49 Hz
  10438.495 Hz
  10518.311 Hz
  10528.239 Hz
  10582.095 Hz
  10926.111 Hz
  10948.411 Hz
  10955.558 Hz
  11538.193 Hz
  11904.741 Hz
  12255.229 Hz
  12613.341 Hz
  12819.942 Hz
  13674.482 Hz
  13731.322 Hz
  14525.312 Hz
  14537.218 Hz
  14549.331 Hz
  14845.453 Hz
  14944.989 Hz
  15246.315 Hz
  18668.239 Hz
  19321.231 Hz
  19347.208 Hz
  30182.932 Hz

Example 10 AM Frequencies Employed for Treatment of Lung Cancer (80 Frequencies so Far Included)

• 304.148 Hz
  694.7 Hz
  694.727 Hz
  708.8 Hz
  708.841 Hz
  1587.811 Hz
  1759.318 Hz
  1873.477 Hz
  2253.704 Hz
  2391.312 Hz
  2454.232 Hz
  2729.929 Hz
  2741.261 Hz
  2761.312 Hz
  2784.491 Hz
  2812.443 Hz
  2855.218 Hz
  2859.495 Hz
  3128.822 Hz
  3139.297 Hz
  3193.212 Hz
  3348.783 Hz
  3360.971 Hz
  3366.311 Hz
  3373.892 Hz
  3440.212 Hz
  3461.322 Hz
  3682.489 Hz
  3727.231 Hz
  3749.882 Hz
  3769.942 Hz
  4131.235 Hz
  4158.393 Hz
  4243.393 Hz
  4347.733 Hz
  4373.411 Hz
  4378.321 Hz
  4416.221 Hz
  4481.242 Hz
  4777.521 Hz
  4798.422 Hz
  4837.241 Hz
  4959.842 Hz
  5013.321 Hz
  5047.523 Hz
  5068.322 Hz
  5371.922 Hz
  5538.432 Hz
  5548.879 Hz
  5679.309 Hz
  5734.143 Hz
  5787.342 Hz
  6445.309 Hz
  6838.434 Hz
  6870.955 Hz
  6879.216 Hz
  7079.411 Hz
  7216.288 Hz
  7376.089 Hz
  7761.289 Hz
  8082.173 Hz
  8281.259 Hz
  8352.189 Hz
  8442.473 Hz
  8773.916 Hz
  8935.752 Hz
  9121.223 Hz
  9181.434 Hz
  9317.913 Hz
  9363.896 Hz
  9736.919 Hz
  9753.321 Hz
  10424.908 Hz
  10452.913 Hz
  10824.609 Hz
  11656.329 Hz
  12748.919 Hz
  15774.291 Hz
  15798.333 Hz
  16510.321 Hz

Example 11 AM Frequencies Employed for Treatment of Leiomyosarcoma (36 Frequencies so Far Included)

• 836.923 Hz
  843.181 Hz
  1411.241 Hz
  2073.721 Hz
  2381.443 Hz
  2711.019 Hz
  2911.329 Hz
  3232.185 Hz
  3518.321 Hz
  3544.209 Hz
  3569.219 Hz
  4233.822 Hz
  4241.321 Hz
  4266.591 Hz
  4337.322 Hz
  4424.112 Hz
  4436.111 Hz
  4485.22 Hz
  5545.521 Hz
  5577.841 Hz
  5631.422 Hz
  5696.184 Hz
  6472.098 Hz
  6558.342 Hz
  6651.276 Hz
  7168.892 Hz
  7406.309 Hz
  7452.528 Hz
  7649.209 Hz
  7808.352 Hz
  9040.313 Hz
  9074.294 Hz
  9189.092 Hz
  9484.512 Hz
  9943.972 Hz
  12086.394 Hz

Example 12 AM Frequencies Employed for Treatment of Mesothelioma (16 Frequencies so Far Included)

• 958.929 Hz
  1713.913 Hz
  1736.782 Hz
  2334.178 Hz
  2607.193 Hz
  3112.974 Hz
  3319.945 Hz
  3449.219 Hz
  3622.312 Hz
  5151.402 Hz
  5887.022 Hz
  5965.922 Hz
  6516.793 Hz
  7224.197 Hz
  9471.152 Hz
  14617.393 Hz

Example 13 AM Frequencies Employed for Treatment of Neuro-Endocrine (30 Frequencies so Far Included)

• 1766.335 Hz
  2408.225 Hz
  2441.502 Hz
  2647.938 Hz
  2741.261 Hz
  3020.212 Hz
  3128.822 Hz
  3238.742 Hz
  3296.431 Hz
  3348.783 Hz
  3360.971 Hz
  3440.212 Hz
  3533.328 Hz
  3666.283 Hz
  4079.282 Hz
  4243.393 Hz
  4426.387 Hz
  5245.818 Hz
  5536.242 Hz
  5548.879 Hz
  5739.422 Hz
  5849.241 Hz
  6291.631 Hz
  6406.891 Hz
  6780.679 Hz
  7151.264 Hz
  7482.245 Hz
  7575.393 Hz
  8359.932 Hz
  9073.418 Hz

Example 14 AM Frequencies Employed for Treatment of Leukemia and Chronic Lymphoid Cancer (17 Frequencies so Far Included)

• 814.413 Hz
  825.145 Hz
  2415.243 Hz
  2436.316 Hz
  2874.432 Hz
  2891.029 Hz
  3361.671 Hz
  5245.452 Hz
  5557.333 Hz
  6850.197 Hz
  6919.322 Hz
  7587.224 Hz
  7629.318 Hz
  8172.405 Hz
  8272.338 Hz
  8438.453 Hz
  12950.331 Hz

Example 15 AM Frequencies Employed for Treatment of Myeloma, Multiple Cancer (20 Frequencies so Far Included)

• 765.196 Hz
  2336.238 Hz
  2372.122 Hz
  2381.443 Hz
  2425.394 Hz
  2656.339 Hz
  2741.261 Hz
  2883.618 Hz
  2919.273 Hz
  3265.323 Hz
  3564.455 Hz
  3580.25 Hz
  3584.291 Hz
  3674.292 Hz
  5249.331 Hz
  7967.311 Hz
  7973.125 Hz
  8049.952 Hz
  8283.329 Hz
  10351.323 Hz

Example 16 AM Frequencies Employed for Treatment of Hodgkin Disease (Lymphoma) (19 Frequencies so Far Included)

• 752.5 Hz
  976.3 Hz
  1558.223 Hz
  2310.912 Hz
  2477.919 Hz
  2560.843 Hz
  3348.783 Hz
  3371.216 Hz
  3605.432 Hz
  3623.198 Hz
  3838.281 Hz
  3838.48 Hz
  5102 Hz
  5696.932 Hz
  5724.231 Hz
  6358.194 Hz
  7472.211 Hz
  8062.121 Hz
  8222.222 Hz

Example 17 AM Frequencies Employed for Treatment of Brain Cancer (57 Frequencies so Far Included)

• 1372.934 Hz
  2318.182 Hz
  2381.443 Hz
  2425.394 Hz
  2442.423 Hz
  2478.973 Hz
  2654.513 Hz
  2661.324 Hz
  2686.105 Hz
  2690.179 Hz
  3249.332 Hz
  3277.509 Hz
  3335.279 Hz
  3348.783 Hz
  3436.211 Hz
  3916.321 Hz
  4031.933 Hz
  4086.091 Hz
  4241.321 Hz
  4318.222 Hz
  4334.33 Hz
  4358.333 Hz
  4393.419 Hz
  4454.194 Hz
  4515.789 Hz
  4619.324 Hz
  4723.937 Hz
  4853.286 Hz
  5289.231 Hz
  5378.099 Hz
  5426.323 Hz
  5640.981 Hz
  6316.211 Hz
  6459.203 Hz
  6474.332 Hz
  6626.572 Hz
  6855.286 Hz
  6915.886 Hz
  6943.386 Hz
  7151.264 Hz
  7182.922 Hz
  7194.897 Hz
  7323.209 Hz
  7390.343 Hz
  7796.221 Hz
  7961.122 Hz
  8128.942 Hz
  8245.109 Hz
  8272.281 Hz
  8358.154 Hz
  8408.121 Hz
  9138.82 Hz
  10719.318 Hz
  11556.241 Hz
  12828.633 Hz
  14515.962 Hz
  14586.765 Hz

• The above Examples reflect AM frequencies determined by a bio-feedback procedure involving very substantial observations and measurements of physiological responses (at certain well defined AM frequencies) by subjects exposed to low energy electromagnetic emission excitation. In general, it is recommended that all of the listed frequencies be applied in the treatment of subjects suffering from the indicated form of cancer. However, a limited number of the listed frequencies also lead to beneficial effects.
• Of note in respect of the above listed frequencies, in particular those Examples including a large number of frequencies, it has earlier on been determined that beneficial therapeutic effects are achieved by application of some but not all of the frequencies listed. However, following on more extended trials, it has been determined that application to subjects of further frequencies enhance the efficacy of treatment and yields therapeutic effects in patients whose tumours have become resistant to therapy. It is accordingly preferred that all of the determined listed frequencies be applied to the subject. The mechanism of including additional frequencies is attributed to either or both of inter-active synergism between applied frequencies or between cells which have been influenced by the treatment and additive effects of the additional frequencies.
• Of further note is the fact that different patients suffering from the same type of tumour cell growth practically invariably exhibit the above-mentioned physiological responses at the same well defined AM frequencies. Furthermore, AM frequencies which differ only very slightly (less than 0.0001% at higher frequencies) from the frequencies listed, in general elicit no physiological response by subjects exposed to excitation at such very slightly different frequency. In view of these determinations, the electronic system of the present invention may be adapted to screen a subject for physiological responses over a broad range of frequencies to determine the presence or absence tumour cells and, if positive, then to note at which defined frequencies physiological responses are elicited. These frequencies will in general match with the defined frequencies listed in one or other of the Examples above or such further examples as may be developed and hence the nature of the tumour will be known. The electronic system of the invention is therefore a valuable diagnostic tool for diagnosing the presence or absence and identities of types of tumour cell growths or cancers. Furthermore, the electronic system of the invention is of value for predicting whether a patient will benefit from the application of a given series of modulation frequencies. The system therefore possesses a capability of predicting responses to treatment, thereby enhancing the possibility to select optimal modes of treatment.
• The sequence of well defined frequencies are preferably applied sequentially for determined periods of time, e.g. 3 seconds for each frequency, but several frequencies may also be applied simultaneously. This means that a cycle of application involving 180 frequencies would take nearly 10 minutes time. Advantageous effects may however also arise from applying individual well defined frequencies for differing time periods, e.g. some for 3 seconds, some for 6 seconds, etc. . . . .
• Therapeutic dosages to be applied to a subject suffering from the presence of tumour cell growth or cancer are determined by the time of application of the low energy electromagnetic emissions to the subject and will depend on the nature of the cancer and the overall condition of the subject. In general, however, greatest experience has been gained in treating terminally ill subjects expected to survive no longer than about three months and who have agreed to discontinue alternative forms of cancer treatments such as chemo-therapy or radioactive treatment. In these severe cases, lengthy times of treatment are recommended, e.g. 3 times 1 hour daily treatment. However, with the development of alternative forms of application, i.e. other than by means of a mouth probe, continuous application is possible and is likely to enhance compliance and the efficacy of the treatment.
• While the invention has been described with specific embodiments, other alternatives, modifications, and variations will be apparent to those skilled in the art. Accordingly, it will be intended to include all such alternatives, modifications, and variations within the spirit and scope of the appended claims.

Claims (19)

1-18. (canceled)

19. An electronic system activatable by electrical power and structured to influence cellular functions or malfunctions in a warm-blooded mammalian subject, said electronic system comprising at least one controllable low energy electromagnetic energy generator circuit for generating one or more high frequency carrier signals, at least one data processor constructed and arranged for communication with the at least one generator circuit and for receiving control information from a source of control information, said at least one generator circuit including at least one amplitude modulation control signal generator for controlling amplitude modulated variations of the one or more high frequency carrier signals, said at least one generator circuit furthermore including at least one programmable amplitude modulation frequency control signal generator for controlling a frequency at which amplitude modulations are generated, the system furthermore comprising a connection position for connection to an electrically conductive applicator for applying to the warm-blooded mammalian subject one or more amplitude-modulated low energy emissions at a program-controlled frequency, wherein said at least one programmable amplitude frequency control generator is adapted to accurately control the frequency at which said amplitude modulations are generated to within an accuracy of at least 1000 ppm relative to one or more determined or predetermined reference amplitude modulation frequencies selected from within a range of 0.01 Hz to 70 kHz and wherein said source of control information includes reference amplitude modulation frequency control information which comprises at least a significant proportion (in excess of 50%) of accurately defined reference amplitude modulation frequencies listed in any one of Examples A, B and 1 to 17, or all of said accurately defined frequencies or yet further accurately defined frequencies, or combinations thereof.

20. The system according to claim 19, wherein the frequency of one or more of the amplitude modulations generated are controllable to within an accuracy of 100 ppm relative to the one or more determined or predetermined reference amplitude modulation frequencies.

21. The system according to claim 20, wherein the frequency of one or more of the amplitude modulations generated are controllable to within an accuracy of 10 ppm relative to the one or more determined or predetermined reference amplitude modulation frequencies.

22. The system according to claim 21, wherein the frequency of one or more of the amplitude modulations generated are controllable to within an accuracy of about 1 ppm relative to the one or more determined or predetermined reference amplitude modulation frequencies.

23. The system according to claim 19, wherein the one or more amplitude modulated low energy emissions generated are maintained at a stability during emission of at least 10⁻⁵.

24. The system according to claim 23, wherein a stability of at least 10⁻⁶ is maintained.

25. The system according to claim 24, wherein a stability of at least 10⁻⁷ is maintained.

26. The system according to claim 19, wherein said at least one controllable generator circuit is controllable by amplitude modulation control signals which lead to various forms of amplitude modulation wave forms being generated.

27. The system according to claim 26, wherein the amplitude modulation wave forms are selected from sinusoidal, square, triangular or multiple combinations thereof.

28. The system according to claim 26, wherein the at least one generator circuit is controllable by amplitude modulation control signals which generate a plurality of amplitude modulation wave forms, either sequentially or simultaneously.

29. The system according to claim 19, wherein the one or more high frequency carrier signals generated by the at least one generator circuit are selected from one or more high frequencies selected from about 27 MHz, 433 MHz and 900 MHz.

30. The system according to claim 19, wherein the system further comprises one or more interfaces communicating with the at least one data processor, and wherein the control information is transferable to said one or more interfaces and hence to the at least one data processor to enable command signals responsive to received control information to be communicated to the at least one generator circuit by the at least one data processor.

31. The system according to claim 30, wherein the control information is transferable over a communication link to the at least one data processor via the one or more interfaces communicating with the at least one data processor.

32. The system according to claim 30, wherein the control information is stored in an information storage device and wherein the control information is transferable to the at least one data processor via said one or more interfaces communicating with the at least one data processor.

33. The system according to claim 30, wherein the system further comprises a user identification device communicating with at least one of the at least one data processor to enable the system to be activated for use only by the user.

34. The system according to claim 19, further comprising a monitor comprising monitoring software for monitoring the amplitude and the amplitude modulation frequency of the amplitude modulated low energy electromagnetic emissions generated by the at least one generator circuit.

35. The system according to claim 19, wherein the determined or predetermined amplitude modulation frequency control information is determined or predetermined by a bio-feedback process involving observations or measurements of physiological reactions by the subject during a time that cellular functions of the subject are excited by exposing the subject to emissions of high frequency carrier signals amplitude modulated at a series of amplitude modulation frequencies.

36. The system according to claim 35, wherein the determined or predetermined frequencies are employed as a mode to identify a nature of a tumor or cancer harbored by the warm-blooded mammalian subject.

Images